Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

MHRA approves Venclyxto for newly diagnosed AML
MHRA approves Venclyxto for newly diagnosed AML
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AbbVie and Roche’s Venclyxto for the treatment of newly diagnosed acute myeloid leukaemia (AML).
Third member of FDA expert panel exits amid Alzheimer's drug flap
Third member of FDA expert panel exits amid Alzheimer's drug flap
The FDA's controversial decision to approve Biogen and Eisai's Alzheimer's disease treatment Aduhelm (aducanumab) has prompted a third member to resign from the advisory committee ...
EU Adds Another Rare Blood Condition as Side Effect of AstraZeneca Shot
EU Adds Another Rare Blood Condition as Side Effect of AstraZeneca Shot
(Reuters) -Europe's drug regulator on Friday identified another very rare blood condition as a potential side effect of AstraZeneca's COVID-19 vaccine and said it was looking into case...
Research identifies potential antiviral compound for COVID-19, flu, different viral an infection
Research identifies potential antiviral compound for COVID-19, flu, different viral an infection
UMass Medical School scientists Katherine A.
Astellas’ Xtandi bags NICE approval in prostate cancer
Astellas’ Xtandi bags NICE approval in prostate cancer
Astellas’ oral treatment Xtandi has received approval from the National Institute for Health and Care Excellence (NICE) for the treatment of metastatic hormone-sensitive prostate cancer (...
Bayer subsidiary doses first patient with Parkinson’s disease cell therapy
Bayer subsidiary doses first patient with Parkinson’s disease cell therapy
German pharma company Bayer has announced that it has made progress in its ‘two-pronged’ approach to deliver cell and gene therapy candidates for the treatment of Parkinson’s disease.
Pandemic inevitably slows pharma M&A activity but appetite for deals remains
Pandemic inevitably slows pharma M&A activity but appetite for deals remains
The initial outbreak of the COVID-19 pandemic delayed merger and acquisitions in the pharma sector, but evidence points to an uptick in activity because the rationale for sealing deals hasn’t change...
Biogen grilled on hefty Alzheimer's drug price
Biogen grilled on hefty Alzheimer's drug price
A day after the FDA's landmark decision to grant accelerated approval to Biogen's Alzheimer's disease drug Aduhelm (aducanumab), company executives on Tuesday were asked to explain...
With $1.2B deal for molnupiravir, U.S. bets on Merck's oral COVID-19 antiviral
With $1.2B deal for molnupiravir, U.S. bets on Merck's oral COVID-19 antiviral
Merck has struggled to develop therapeutics and vaccines to fight COVID-19.
EmpowerPharm becomes the first Canadian pharmaceutical company with a certified GMP facility fully dedicated to manufacture CBD tablets and capsules
EmpowerPharm becomes the first Canadian pharmaceutical company with a certified GMP facility fully dedicated to manufacture CBD tablets and capsules
BURLINGTON, ON.
On a vaccine roll, Pfizer scores FDA nod for Prevnar 13 follow-up ahead of rival Merck
On a vaccine roll, Pfizer scores FDA nod for Prevnar 13 follow-up ahead of rival Merck
Another year, another major vaccine approval for Pfizer.
AstraZeneca takes PARP battle to court, seeking a larger claim to GSK's key cancer med Zejula: report
AstraZeneca takes PARP battle to court, seeking a larger claim to GSK's key cancer med Zejula: report
GlaxoSmithKline’s $5.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand